The global regenerative medicine market was valued at $28.9 billion in 2021 and it is expected to reach $78.1 billion at a CAGR of 8.8% between 2022 and 2032. The development of gene therapy, together with advancements in stem cell and tissue engineering, is anticipated to drive market expansion. The market has grown as a result of rising regulatory approvals for pharmaceuticals used in advanced therapies.
Stem cell treatment commonly referred to as regenerative medicine uses stem cells or their byproducts to encourage the repair response of sick, malfunctioning, or wounded tissue. It is the next step in the transplantation of organs, replacing donor organs—which are scarce—with cells. Examples include tissue engineering, immunomodulation therapy, and cell therapies (the injection of stem or progenitor cells), which all involve the regeneration of cells using physiologically active chemicals (transplantation of laboratory-grown organs and tissues). Additionally, stem cells are taken from the patient's fat, blood, or bone marrow and employed in regenerative medicine. They are then placed in a medical device called a centrifuge, which allows the doctor to distinguish between the cells and select the best ones for use in the regenerative therapy procedure. Furthermore, stem cell therapy, maybe one of the most well-known forms of regenerative medicine, has received a lot of attention recently in the media. This is because it has been successfully used by physicians to heal joint and tissue injuries.
Source: SAI Research
Additionally, businesses are working together to improve their R&D capabilities to create and market novel cures, ensuring that their clients can access them locally or globally. Due to their excellent effectiveness and reported success rates of up to 80%, stem cell therapies have seen a considerable rise in popularity. It is a cutting-edge form of regenerative medicine that makes use of a distinctive biological element called stem cells. Moreover, the way that researchers view regenerative medicine has changed as a result of technological developments in stem cell-based therapy. The advancement of regenerative medicine has accelerated thanks to improvements in stem cell therapy. For instance, leukemia and other blood illnesses are being treated by haematogenic stem cells. Additionally, nanotechnology is a potent tool for regenerative medicine and creating stem cells. The development of nanofiber scaffolds is now possible thanks to advances in nanofabrication techniques. These would propel the market growth during the forecast period.
The market for regenerative medicines will see significant growth in the cell and tissue-based sectors. Cell and tissue-based therapies are preferred by patients who have the financial means to pay for expensive treatments and who seek a permanent cure for a particular illness. The approval of various unique tissue-engineered regenerative medicine products is another factor contributing to the expectation of growth in the cell and tissue-based therapy market. The increasing number of clinical trials is also one of the significant market trends for regenerative medicines that are driving market expansion.
However, cell and gene therapies, which are a huge achievement in science and medicine, are required for patients with terminal illnesses and serious disorders. These treatments are altering how illnesses are managed and perhaps even healed. Additionally, such treatments will soon allow doctors and other medical professionals to inject genes or cells into patients in place of several medications and operations.
Based on product type, the therapeutics category accounted for the largest share of the market. This segment is also projected to boost the market growth in the future due to the rising development of therapeutics across several emerging countries. Due to its use for various therapeutic purposes and early adoption in clinical application, primary cell-based treatments are among the most advanced medicines now accessible. Moreover, the following year saw a good rate of technology adoption. The primary drivers propelling the growth of this market are the rising funding for research and development of regenerative medicine goods and therapies and the rising use of tissue-engineered products for the treatment of chronic wounds and musculoskeletal ailments.
In terms of application type, the oncology segment holds most of the market share and is anticipated to accelerate the market growth over the forecast period. Effective cancer treatment alternatives have been introduced as a result of high cancer prevalence. Numerous governmental agencies as well as private businesses have invested much in cancer research and the creation of cutting-edge cell therapies. The market would expand as a result of this. The segment for musculoskeletal problems held the biggest market share, nevertheless. This is explained by the increase in the number of elderly people, the expansion of stem cell research, and the rise in the incidence of orthopedic illnesses.
Geographically, North America is the major region that holds the largest share of the regenerative medicine market. Hence, this region is expected to hold its dominant position in the upcoming years. Most of the key players are located in several countries in North America, which is another plus point for the market growth. This is explained by the fact that the U.S. is home to a sizable number of important players. The great volume of clinical trials in this area can be attributed to the accessibility of cutting-edge technologies and the presence of research institutions engaged in the discovery of innovative treatments. The expansion of the healthcare industry, the increased use of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases, the rise in stem cell banking, tissue engineering, and drug discovery in the area are all factors contributing to the growth of the regenerative medicine market in this region. The Asia-Pacific region is also expected to become the second-largest market during the forecast period.
According to the study, key players such as American CryStem Corp (U.S), Amgen (U.S), Astellas Pharma (Japan), Abbott Laboratories (U.S), AstraZeneca (U.K), Avita Medical (U.K), Baxter International (U.S), Bayer AG (Germany), Bristol Myers Squibb (U.S), Integra Lifesciences (U.S), Medtronic (U.S), Nuvasive Inc (U.S), Pfizer (U.S), Styker Corporation (U.S), Smith and Nephew (U.K), Takara Holdings (Japan), Tissue Regenix (U.K), among others are leading the global regenerative medicine market.
|Market Size in 2021||US$ 28.9 Billion|
|Market Volume Projection by 2032||US$ 78.1 Billion|
|Forecast Period 2022 to 2032 CAGR||8.8%|
|Historical Data||2019, 2020 and 2021|
|Forecast Period||2022 to 2032|
By Product Type: Therapeutics, Banks, Tools & Services
By Application Type: Oncology, Musculoskeletal, Wound Care, Dental, Cardiovascular, Ophthalmology & Others
North America, Europe, Asia-Pacific, LAMEA
|Companies covered||American CryStem Corp (U.S), Amgen (U.S), Astellas Pharma (Japan), Abbott Laboratories (U.S), AstraZeneca (U.K), Avita Medical (U.K), Baxter International (U.S), Bayer AG (Germany), Bristol Myers Squibb (U.S), Integra Lifesciences (U.S), Medtronic (U.S), Nuvasive Inc (U.S), Pfizer (U.S), Styker Corporation (U.S), Smith and Nephew (U.K), Takara Holdings (Japan), Tissue Regenix (U.K) & Others|
The Global Regenerative Medicine Market – by Product Type:
The Global Regenerative Medicine Market – by Application Type:
The Global Regenerative Medicine Market – by Regions: